| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
43,980,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
66,200 |
Avg
Vol: |
66,017 |
| 52
Week Range: |
$0.173 - $0.173 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ESSA Pharma is a clinical stage pharmaceutical company. Co. is focused on developing therapies for the treatment of prostate cancer in patients whose disease is progressing despite treatment with care therapies, including anti-androgen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. Co.'s series of investigational compounds, including its product candidate EPI-7386, is used in patients with castration-resistant prostate cancer through anti-hormone-based therapies. The compounds are designed to disrupt the androgen receptor (AR) signaling pathway and prevent AR activation through selective binding to the N-terminal domain of the AR.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
32,482 |
108,953 |
1,035,445 |
| Total Buy Value |
$0 |
$154,487 |
$574,148 |
$3,342,196 |
| Total People Bought |
0 |
2 |
2 |
4 |
| Total Buy Transactions |
0 |
2 |
4 |
11 |
| Total Shares Sold |
2,082 |
78,475 |
78,475 |
351,315 |
| Total Sell Value |
$16,565 |
$798,400 |
$798,400 |
$1,527,452 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
3 |
7 |
7 |
12 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bb Biotech Ag |
10% Owner |
– – • |
2022-07-15 |
4 |
B |
$3.13 |
$756,798 |
D/D |
241,665 |
5,579,583 |
2.45 |
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2022-07-14 |
4 |
B |
$2.79 |
$969,428 |
D/D |
347,204 |
5,337,918 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2022-07-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,561,841 |
|
- |
|
| Parkinson David Ross |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
B |
$2.96 |
$14,456 |
D/D |
4,887 |
32,108 |
2.81 |
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2022-04-27 |
4 |
S |
$5.85 |
$146,925 |
D/D |
(25,100) |
4,990,714 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-08-18 |
4 |
B |
$8.88 |
$2,218,800 |
D/D |
250,000 |
5,015,814 |
2.45 |
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2021-08-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,765,814 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2021-02-22 |
4 |
B |
$27.00 |
$1,539,000 |
D/D |
57,000 |
957,244 |
2.39 |
- |
|
| Berger Franklin M |
Director |
– • – |
2020-12-03 |
4 |
OE |
$3.23 |
$153,701 |
D/D |
42,207 |
900,244 |
|
- |
|
| Martin John Alexander |
Director |
– • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,299 |
|
- |
|
| Schwarzman Stephen A |
10% Owner |
– – • |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,573,053 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
858,037 |
|
- |
|
| Wood David S. |
Chief Financial OfficerOfficer |
• – – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,890 |
|
- |
|
| Parkinson David Ross |
Chief Executive OfficerOfficer |
• • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,070 |
|
- |
|
| Virsik Peter |
Chief Operating OfficerOfficer |
• – – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,570 |
|
- |
|
| Thorell Marella |
Director |
– • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,881 |
|
- |
|
| Requadt Scott |
Director |
– • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
| Glickman Richard M |
Director |
– • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,750 |
|
- |
|
43 Records found
|
|
Page 2 of 2 |
|
|
